ClinicalTrials.gg
CompletedNCT01887626Updated Sep 18, 2013

Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.

A Phase 1 interventional study of Ticagrelor 90 mg whole tablet and Ticagrelor 90 mg tablet crushed in Bioavailability Heathy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-18.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.

Read the detailed description

Study to evaluate the bioavailability of the crushed ticagrelor tablets when administered orally or through nasogastric tubes compared to whole ticagrelor tablets given orally

02

Conditions studied

  • Bioavailability Heathy Volunteers

Keywords

  • Phase 1, pharmacokinetic, safety, Ticagrelor
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture
  • Have a between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds [lbs]) and no more than 100 kg (220 lbs).
  • Provision of signed and dated, written prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
  • History of haemophilia, von Willebrand's disease, lupus anticoagulant or other diseases/syndromes that can either alter or increase the propensity for bleeding
  • A personal history of vascular abnormalities including aneurysms; a personal history of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior to the screeening visit; or history suggestive of peptic ulcer disease
  • History of frequent and/or significant nose bleed or clinically significant non traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk, as judged by the Investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    A

    Ticagrelor 90 mg as a whole tablet

    Drug: Ticagrelor 90 mg whole tablet

  • Experimental
    B

    Ticagrelor 90 mg tablet crushed and suspended in water

    Drug: Ticagrelor 90 mg tablet crushed

  • Experimental
    C

    Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach

    Drug: Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube

Interventions

  • Ticagrelor 90 mg whole tablet administered as a single oral dose

  • Ticagrelor 90 mg crushed and suspended in water

  • DrugDispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube

    Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach

06

What researchers measure

Primary outcomes

  1. Description of the pharmacokinetic(PK) profile in terms of plasma concentration-time curve (AUC) of ticagrelor

    Time frame: PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

  2. Description of the pharmacokinetic(PK) profile in terms of AUC of the active metabolite of ticagrelor

    Time frame: PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

  3. Description of the pharmacokinetic(PK) profile in terms of maximum plasma concentration (Cmax) of ticagrelor

    Time frame: PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

  4. Description of the pharmacokinetic(PK) profile in terms of Cmax of the active metabolite of ticagrelor

    Time frame: PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose

Secondary outcomes

  1. Description of the safety profile in terms of adverse events (AE)

    Time frame: From first dose through to the follow-up visit.

  2. Description of the safety profile in terms of laboratory variables

    Time frame: Safety labs at screening, Day -1, Day 3 (48 hours after treatment) and follow-up

  3. Description of the safety profile in terms of vital signs

    Time frame: Vital signs at screening, pre-dose, 1 h, 3, 6, 12 and 24 hours post-dose, Day 3 for all treatment periods and follow-up

  4. Description of the safety profile in terms of physical examination findings

    Time frame: Physical examination at screening, pre-dose, Day 3 and follow-up

  5. Description of the safety profile in terms of Electrocardiogram (ECG)

    Time frame: ECGs at screening, Day 3 and follow-up

07

Study locations

1 site
  • Research Site
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2013
First posted
Jun 27, 2013
Start
Jul 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Sep 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01887626
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 27, 2013
Start date
Jul 2013
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Sep 18, 2013

Study contacts

Judith Hsia, MD
study director · AstraZeneca, Wilmington, US
Mirjana Kujacic, MD
study chair · AstraZeneca Mölndal, Sweden
Saeed Kahn, MBBS
principal investigator · Quintiles London, United Kingdom

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion